Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
Panaccione
R
R
Division of Gastroenterology, Department of Medicine, University of Calgary, Calgary, AB, Canada. rpanacci@ucalgary.ca
Colombel
J-F
JF
Sandborn
W J
WJ
Rutgeerts
P
P
D'Haens
G R
GR
Robinson
A M
AM
Chao
J
J
Mulani
P M
PM
Pollack
P F
PF
D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D003424:Crohn Disease / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab